Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
21 pending office actions • 16 art units • 21 examiners • 0 of 21 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
The Governors of the University of Alberta currently have 20 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 16 distinct art units, demonstrating technical diversity within the portfolio's active applications. The company is interacting with 20 distinct examiners, which means that every pending office action is being reviewed by a different person.
The busiest examiner for the portfolio is FAN, WEIHUA, who is responsible for 1 pending office action. Because there are 20 distinct examiners for the 20 pending office actions, the workload is distributed across the patent office's staff without concentration. The 16 distinct art units indicate that the Biotechnology & Pharmaceuticals filings cover a range of sub-specialties, requiring the university to manage 20 separate prosecution tracks simultaneously.
This level of dispersion suggests that the portfolio is not concentrated in a niche but rather spans a spectrum of the technology area. Practitioners must account for the individual preferences of 20 distinct examiners while maintaining consistency across 16 distinct art units. The 1 pending office action assigned to FAN, WEIHUA is part of a broad engagement within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (19%) |
| §103 only | 5 (24%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 1 (5%) |
| Multi-statute (no §101) | 10 (48%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAN, WEIHUA | 1 | 83.4% | +12.6% |
| HO, ANH N | 1 | 80.7% | +14.2% |
| BUCKLE JR, JAMES J | 1 | 65.5% | +14.9% |
| REICHERT, RACHELLE LEIGH | 1 | 30.2% | +33.2% |
| GOLOBOY, JAMES C | 1 | 63.7% | +8.7% |
| PROSSER, ALISSA J | 1 | 15.7% | +11.2% |
| KURTZ, BENJAMIN M | 1 | 56.8% | +17.6% |
| OGUNTADE, ELIZABETH BISOLA | 1 | 0.0% | +0.0% |
| FOLEY, SHANON A | 1 | 73.3% | +18.1% |
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625545 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE | HUDSON, AMY ROSE | 71d overdue |
| 17886881 | THREE-DIMENSIONAL (3D) HERNIA PLUG DEVICE AND A METHOD OF MANUFACTURING THEREOF | DORNA, CARRIE R | 43d overdue |
| 18546637 | PULSE PROTEIN GELATION | KIM, BRYAN | 8d |
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | PROSSER, ALISSA J | 53d |
| 19162601 | MODIFIED NUCLEIC ACID SEQUENCE FOR CONFERRING CLUBROOT RESISTANCE TO CANOLA AND METHODS OF PRODUCING SAME | FAN, WEIHUA | — |
| 18837460 | SYSTEMS AND DEVICES FOR COUPLING METABOLOMICS DATA WITH DIGITAL MONITORS FOR PRECISION HEALTH | REICHERT, RACHELLE LEIGH | — |
| 18737311 | IONIC LIQUID DEMULSIFIERS FOR EMULSION SEPARATION AND BITUMEN DEWATERING | GOLOBOY, JAMES C | — |
| 18440027 | MICROBUBBLE-ENHANCED COLD PLASMA WATER ACTIVATION | KURTZ, BENJAMIN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | PROSSER, ALISSA J | 53d |
| 19162601 | MODIFIED NUCLEIC ACID SEQUENCE FOR CONFERRING CLUBROOT RESISTANCE TO CANOLA AND METHODS OF PRODUCING SAME | FAN, WEIHUA | — |
| 19217642 | ANTENNA USING EMBEDDED MTM-EBG UNIT CELLS | HO, ANH N | — |
| 18799207 | SMART SELF-CENTERED SHEAR WALL SYSTEM | BUCKLE JR, JAMES J | — |
| 18837460 | SYSTEMS AND DEVICES FOR COUPLING METABOLOMICS DATA WITH DIGITAL MONITORS FOR PRECISION HEALTH | REICHERT, RACHELLE LEIGH | — |
| 18440027 | MICROBUBBLE-ENHANCED COLD PLASMA WATER ACTIVATION | KURTZ, BENJAMIN M | — |
| 18391501 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | FOLEY, SHANON A | — |
| 18529858 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1672 | 2 |
| 3646 | 2 |
| 1693 | 2 |
| 1663 | 1 |
| 2845 | 1 |
| 3633 | 1 |
| 3686 | 1 |
| 1619 | 1 |
| 1779 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19162601 | MODIFIED NUCLEIC ACID SEQUENCE FOR CONFERRING CLUBROOT RESISTANCE TO CANOLA AND METHODS OF PRODUCING SAME | FAN, WEIHUA | 1663 | §101§102§112 | Non-Final OA | — | Pending | Sep 05, 2025 |
| 19217642 | ANTENNA USING EMBEDDED MTM-EBG UNIT CELLS | HO, ANH N | 2845 | §103 | Non-Final OA | — | Pending | May 23, 2025 |
| 18799207 | SMART SELF-CENTERED SHEAR WALL SYSTEM | BUCKLE JR, JAMES J | 3633 | §103 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18837460 | SYSTEMS AND DEVICES FOR COUPLING METABOLOMICS DATA WITH DIGITAL MONITORS FOR PRECISION HEALTH | REICHERT, RACHELLE LEIGH | 3686 | §101§102§112 | Final Rejection | — | Pending | Aug 09, 2024 |
| 18737311 | IONIC LIQUID DEMULSIFIERS FOR EMULSION SEPARATION AND BITUMEN DEWATERING | GOLOBOY, JAMES C | — | §102§103§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | PROSSER, ALISSA J | 1619 | §103§112 | Non-Final OA | 53d | Pending | Mar 13, 2024 |
| 18440027 | MICROBUBBLE-ENHANCED COLD PLASMA WATER ACTIVATION | KURTZ, BENJAMIN M | 1779 | §103§112 | Final Rejection | — | Pending | Feb 13, 2024 |
| 18574221 | MIGRATION OF HUMAN PERIPHERAL LEUKOCYTES IN RESPONSE TO CHEMOTACTIC FACTORS DURING PREGNACY | OGUNTADE, ELIZABETH BISOLA | 1654 | §101§103§112DP | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18391501 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | FOLEY, SHANON A | 1671 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18529858 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §103§112DP | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18520057 | E1E2 HCV VACCINES AND METHODS OF USE | ZOU, NIANXIANG | 1671 | §101§103Other | Final Rejection | — | Pending | Nov 27, 2023 |
| 18506083 | SEMICONDUCTOR SYSTEM WITH WAVEGUIDE ASSEMBLY WITH RF SIGNAL IMPREDANCE CONTROLLABLE BY APPLIED ELECTROMAGNETIC RADIATION | MOORE, WHITNEY | 3646 | §102§103Other | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18279517 | THE USE OF EMPAGLIFLOZIN FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Final Rejection | 46d overdue | Pending | Aug 30, 2023 |
| 18546637 | PULSE PROTEIN GELATION | KIM, BRYAN | 1792 | §102§103§112 | Non-Final OA | 8d | Pending | Aug 30, 2023 |
| 18037196 | CYCLOTRON TARGET AND LANTHANUM THERANOSTIC PAIR FOR NUCLEAR MEDICINE | DAVIS, SHARON M | 3646 | §103 | Non-Final OA | 35d overdue | Pending | May 16, 2023 |
| 17800516 | Inhibitors of Human Herpesviruses | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Aug 17, 2022 |
| 17886881 | THREE-DIMENSIONAL (3D) HERNIA PLUG DEVICE AND A METHOD OF MANUFACTURING THEREOF | DORNA, CARRIE R | 3791 | §102§103 | Final Rejection | 43d overdue | Pending | Aug 12, 2022 |
| 17625545 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | 71d overdue | Pending | Jan 07, 2022 |
| 17596491 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | MARTIN, KEVIN STEPHEN | 1624 | §102§112 | Final Rejection | — | Pending | Dec 10, 2021 |
| 17599282 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | HIBSHMAN, SARAH GRACE | 1693 | §103 | Non-Final OA | — | Pending | Sep 28, 2021 |
| 17187678 | RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS | SALVOZA, M FRANCO G | 1672 | §103§112 | Non-Final OA | — | Pending | Feb 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial